Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Assessing safety and tolerability of MT-5111 in patients with HER2+ tumors

Brian Van Tine • 4 Jun 2022
ASCO 2022
General MT-5111

Brian A. Van Tine, MD, PhD, Washington University School of Medicine in St.Louis, St Louis, MO, discusses results from a Phase I study (NCT04029922) of MT-511, a novel shiga toxin-conjugated recombinant fusion protein targeting HER2 in HER2-expressing solid tumors. The investigational therapy is well tolerated to-date with no clinically significant immuno- and cardiotoxicity, with the dose-escalation portion of the trial currently being conducted. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Brian Van Tine

Assessing the future role of catequentinib, a novel TKI, in sarcomas
1:26
Assessing the future role of catequentinib, a novel TKI, in sarcomas
Brian Van Tine • 2 Jul 2025
Combining olaparib and temozolomide in uterine leiomyosarcoma: a promising synergy
1:14
Combining olaparib and temozolomide in uterine leiomyosarcoma: a promising synergy
Brian Van Tine • 2 Jun 2025
Alliance A092104: olaparib and temozolomide in uterine leiomyosarcoma
1:56
Alliance A092104: olaparib and temozolomide in uterine leiomyosarcoma
Brian Van Tine • 2 Jun 2025
What does the future hold for CAR T-cells in sarcoma management?
0:54
What does the future hold for CAR T-cells in sarcoma management?
Brian Van Tine • 4 Jun 2023

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals